With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
Teams studying kidney and skin cancers independently implicated SWI/SNF chromatin remodeling mutations in checkpoint blockade immunotherapy response.
In Science this week: gut microbes affect how cancer patients respond to immunotherapy, and more.
A pair of papers point to potential gut microbial contributions to checkpoint blockade immunotherapy response in individuals with lung, kidney, or skin cancer.
When investigators retraced recurrent mutations, expression changes, and methylation shifts in hundreds of Wilms tumor case, they identified two main pathways.
The test, developed with Pfizer, could identify renal cancer patients who would experience recurrence, but not who would benefit from adjuvant Sutent.
The grant will fund a collaboration investigating whether genomic signatures and other biomarkers can be used in clinical diagnosis and monitoring of kidney cancer.
In PLOS this week: papillary renal cell carcinoma mutations, role of microRNAs in cold- and alkaline-adapted fish, and more.
The University of California, Los Angeles-led team said the approach outperformed two established classification methods.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.